We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer Extends Its Reach in Cancer, Immunology Research With Vividion Purchase
Bayer Extends Its Reach in Cancer, Immunology Research With Vividion Purchase
In the latest in a series of acquisitions aimed at quickly ramping up its portfolio of new drugs, Bayer is acquiring San Diego, Calif.-based biopharmaceutical firm Vividion Therapeutics in a deal worth up to $2 billion.